XBI vs. LFSC
Compare and contrast key facts about SPDR S&P Biotech ETF (XBI) and F/m Emerald Life Sciences Innovation ETF (LFSC).
XBI and LFSC are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006. LFSC is an actively managed fund by F/m Investments. It was launched on Oct 30, 2024.
Performance
XBI vs. LFSC - Performance Comparison
Loading graphics...
XBI vs. LFSC - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
XBI SPDR S&P Biotech ETF | 4.76% | 35.89% | -7.18% |
LFSC F/m Emerald Life Sciences Innovation ETF | -4.45% | 56.54% | -6.02% |
Returns By Period
In the year-to-date period, XBI achieves a 4.76% return, which is significantly higher than LFSC's -4.45% return.
XBI
- 1D
- 7.53%
- 1M
- 0.28%
- YTD
- 4.76%
- 6M
- 27.90%
- 1Y
- 58.08%
- 3Y*
- 19.00%
- 5Y*
- -1.29%
- 10Y*
- 9.32%
LFSC
- 1D
- 6.16%
- 1M
- -3.82%
- YTD
- -4.45%
- 6M
- 17.66%
- 1Y
- 55.83%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
XBI vs. LFSC - Expense Ratio Comparison
XBI has a 0.35% expense ratio, which is lower than LFSC's 0.54% expense ratio.
Return for Risk
XBI vs. LFSC — Risk / Return Rank
XBI
LFSC
XBI vs. LFSC - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Biotech ETF (XBI) and F/m Emerald Life Sciences Innovation ETF (LFSC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| XBI | LFSC | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 2.02 | 1.93 | +0.09 |
Sortino ratioReturn per unit of downside risk | 2.70 | 2.65 | +0.05 |
Omega ratioGain probability vs. loss probability | 1.34 | 1.33 | +0.01 |
Calmar ratioReturn relative to maximum drawdown | 3.72 | 3.20 | +0.52 |
Martin ratioReturn relative to average drawdown | 13.98 | 8.96 | +5.02 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| XBI | LFSC | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.02 | 1.93 | +0.09 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.04 | — | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.29 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.36 | 0.94 | -0.58 |
Correlation
The correlation between XBI and LFSC is 0.83, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
XBI vs. LFSC - Dividend Comparison
XBI's dividend yield for the trailing twelve months is around 0.34%, while LFSC has not paid dividends to shareholders.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
XBI SPDR S&P Biotech ETF | 0.34% | 0.37% | 0.15% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% |
LFSC F/m Emerald Life Sciences Innovation ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
XBI vs. LFSC - Drawdown Comparison
The maximum XBI drawdown since its inception was -63.89%, which is greater than LFSC's maximum drawdown of -29.74%. Use the drawdown chart below to compare losses from any high point for XBI and LFSC.
Loading graphics...
Drawdown Indicators
| XBI | LFSC | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -63.89% | -29.74% | -34.15% |
Max Drawdown (1Y)Largest decline over 1 year | -13.39% | -16.25% | +2.86% |
Max Drawdown (5Y)Largest decline over 5 years | -55.04% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -63.89% | — | — |
Current DrawdownCurrent decline from peak | -26.17% | -11.08% | -15.09% |
Average DrawdownAverage peak-to-trough decline | -20.91% | -8.25% | -12.66% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.71% | 5.80% | -2.09% |
Volatility
XBI vs. LFSC - Volatility Comparison
SPDR S&P Biotech ETF (XBI) has a higher volatility of 11.60% compared to F/m Emerald Life Sciences Innovation ETF (LFSC) at 10.35%. This indicates that XBI's price experiences larger fluctuations and is considered to be riskier than LFSC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| XBI | LFSC | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.60% | 10.35% | +1.25% |
Volatility (6M)Calculated over the trailing 6-month period | 19.25% | 19.97% | -0.72% |
Volatility (1Y)Calculated over the trailing 1-year period | 29.24% | 29.24% | 0.00% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 32.23% | 29.31% | +2.92% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 32.15% | 29.31% | +2.84% |